AERAMI THERAPEUTICS LOGO-VERTICAL- COLOR.png
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China
February 09, 2021 09:00 ET | Aerami Therapeutics Inc
DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
March 17, 2020 07:30 ET | Abeona Therapeutics Inc.
Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17,...
CENTOGENElogo.jpg
CENTOGENE Expands Executive Leadership Team
December 06, 2019 06:00 ET | Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany, Dec. 06, 2019 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG) today announced the expansion of its executive leadership team with the appointment of Philip...
CENTOGENElogo.jpg
CENTOGENE Announces Pricing of Initial Public Offering
November 07, 2019 03:12 ET | Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENElogo.jpg
CENTOGENE Announces Proposed Initial Public Offering of Common Shares
October 28, 2019 08:54 ET | Centogene AG
CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world...
Abeona Therapeutics.jpg
Abeona Announces Participation at Upcoming Conferences
September 28, 2018 08:45 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
May 17, 2018 09:20 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Upcoming Conference Participation
February 21, 2018 08:45 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
November 15, 2017 08:25 ET | Abeona Therapeutics Inc.
Investor Conference Call to be held Monday, November 20th at 10:00 am ETGlobal enrollment continues in ABO-102 trial for MPS IIIAScreening initiated in ABO-101 Phase 1/2 trial for MPS IIIBPivotal...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
October 16, 2017 08:26 ET | Abeona Therapeutics Inc.
Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programsCompany receives infusion of an additional $5 million from exercise of...